A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma

NCT ID: NCT06415669

Last Updated: 2024-05-29

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-05-19
• Study Completion Date: 2027-05-19

Brief Summary

To evaluate the initial efficacy and safety of paclitaxel for injection (albumin-bound) in combination with apatinib mesylate and adebrelimab in the treatment of locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma following the progression of previous immunotherapy.

Conditions

Gastric/Gastroesophageal Junction Adenocarcinoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Single arm

Paclitaxel for injection (albumin-bound) in combination with Apatinib mesylate and adebrelimab

Group Type: EXPERIMENTAL

Paclitaxel for injection (albumin-bound)

Intervention Type: DRUG

100 mg/m2, day 1, day 8, every 21 days for a cycle.

Adebrelimab

Intervention Type: DRUG

20mg/kg or 1200mg, the first day, every 21 days as a cycle.

Apatinib mesylate

Intervention Type: DRUG

250mg once a day for 5 consecutive days and discontinue for 2 days

Interventions

Paclitaxel for injection (albumin-bound)

100 mg/m2, day 1, day 8, every 21 days for a cycle.

Intervention Type: DRUG

Adebrelimab

20mg/kg or 1200mg, the first day, every 21 days as a cycle.

Intervention Type: DRUG

Apatinib mesylate

250mg once a day for 5 consecutive days and discontinue for 2 days

Intervention Type: DRUG

Other Intervention Names

SHR-1316

Eligibility Criteria

Inclusion Criteria

• 1) Age: 18 ~ 75 years old, male and female;
• 2) ECOG score: 0 or 1;
• 3) Patients with unresectable locally advanced or metastatic gastric cancer/gastroesophageal junction adenocarcinoma confirmed by histopathology;
• 4) Patients who have received at least first-line immunotherapy progression or intolerance in the past, and the number of previous systemic treatment lines does not exceed 2 lines; The best curative effect of frontline containing PD-1/PD-L1 was CR, PR or SD;
• 5) According to the evaluation criteria for the efficacy of solid tumors (RECIST 1.1), there should be at least one measurable lesion that has not received local treatment such as radiotherapy (lesions located in the area of previous radiotherapy can also be selected as target lesions if progression is confirmed);
• 6) The major organs function normally and meet the following criteria
• a. In the past 14 days without the use of granulocyte colony-stimulating factor, the absolute value of neutrophil (ANC) ≥1.5x109 /L;
• b. Platelets ≥100×109 /L in the past 14 days without blood transfusion;
• c. Hemoglobin >90g/L in the last 14 days without blood transfusion or use of erythropoietin;
• d. Total bilirubin ≤1.5× upper limit of normal (ULN);
• e. aspartate aminotransferase (AST), alanine aminotransferase (ALT) in

≤2.5×ULN (ALT or AST ≤5×ULN for patients with liver metastasis);

• f. Serum creatinine ≤1.5×ULN and creatinine clearance (calculated by Cockcroft-Gault formula) ≥40 ml/min;
• g. Good coagulation function, defined as International standardized ratio (INR) or prothrombin time (PT) ≤1.5 times ULN;
• h. The myocardial enzyme profile is within the normal range (if the researchers comprehensively judge that the simple laboratory abnormality is not clinically significant, it is also allowed to be included);
• 7) Expected survival ≥3 months;
• 8) Women of reproductive age should agree to use contraceptives (such as Iuds, contraceptives, or condoms) during the study period and for 6 months after the study ends; Have a negative serum or urine pregnancy test within 7 days prior to study enrollment and must be a non-lactating patient; Men should consent to patients who must use contraception during the study period and for 6 months after the end of the study period;
• 9) Sign informed consent.

Exclusion Criteria

• 1) Patients who have previously received paclitaxel chemotherapy; Patients with neoadjuvant or adjuvant treatment with taxoid drugs and disease progression more than 6 months after the last chemotherapy were excluded;
• 2) HER2-positive patients;
• 3) Patients who are taking immunosuppressants or systemic hormone therapy for immunosuppressive purposes (dose >10mg/ day prednisone or other therapeutic hormone) and continue to use within 2 weeks before enrollment;
• 4) Patients with severe liver and kidney insufficiency or heart insufficiency;
• 5) have multiple factors that affect oral drugs (such as inability to swallow, gastrointestinal resection, chronic diarrhea, and intestinal obstruction);
• 6) Patients with brain metastases accompanied by symptoms or symptom control for less than 3 months;
• 7) Patients who are known to be allergic to any investigational drug or drug excipient;
• 8) Pregnant or lactating female patients;
• 9) Patients who underwent major surgical procedures (craniotomy, thoracotomy, or laparotomy) or had unhealed surgical wounds, ulcers, or fractures within 4 weeks prior to initial dosing, except for patients ≥2 weeks after surgery and patients with old fractures that the investigator determined could be treated with the study drug;
• 10) Patients with moderate to severe ascites accompanied by clinical symptoms requiring repeated drainage; Patients with uncontrolled or clinical symptoms of pleural effusion or pericardial effusion;
• 11) Patients with clinically significant electrolyte disorders;
• 12) People with acute or chronic active hepatitis B or hepatitis C: hepatitis B virus (HBV) DNA > 2000IU/ml or 104 copies /ml; Hepatitis C virus (HCV) RNA > 103 copies /ml; Hepatitis B surface antigen (HbsAg) and anti-HCV antibody positive patients;
• 13) Patients with central nervous system metastasis, but with no clinical symptoms or accompanied by clinical symptoms after treatment, disease control and stable time ≥4 weeks can be enrolled; To meet the need for measurable lesions outside the central nervous system, hormone therapy should be discontinued 14 days before the first study of medication
• 14) Any life-threatening bleeding event within the previous 3 months, including patients requiring transfusion therapy, surgery or local therapy, and ongoing medication;
• 15) Patients with a history of arteriovenous thromboembolism events, including myocardial infarction, unstable angina pectoris, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis, or any other severe thromboembolism within the past 6 months. The exception is implantable intravenous infusion port or catheter-derived thrombosis, or superficial venous thrombosis, which is stable after conventional anticoagulant therapy. Allow patients to prophylactically use small doses of low molecular weight heparin (e.g., enoxaparin 40 mg/ day);
• 16) Uncontrolled hypertension, systolic blood pressure > 160 MMHG or diastolic blood pressure > 100mmHg after optimal medical treatment, hypertensive crisis or hypertensive encephalopathy history;
• 17) Symptomatic congestive heart failure (New York Heart Association Grade II-IV). Symptomatic or poorly controlled arrhythmia. Patients with a history of congenital long QT syndrome or a QTc > 500ms (calculated using the Fridericia method) corrected at screening;
• 18) For patients who received radiation therapy more than 4 weeks before the first treatment, all of the following conditions must be met to be enrolled: there is no current toxic reaction related to radiation therapy, no need to take glucocorticoids, and radiation pneumonia, radiation hepatitis, and radiation enteritis are excluded;
• 19) Patients with previous or current pulmonary diseases such as pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, drug-related pneumonia, and severe impairment of lung function;
• 20) Human immunodeficiency virus (HIV) infection (HIV 1/2 antibody positive), known syphilis infection;
• 21) Patients with unhealed wounds, fractures, gastric and duodenal ulcers, persistent positive stool occultiblood, ulcerative colitis, or other conditions that researchers have determined may cause gastrointestinal bleeding or perforation;
• 22) All adverse events during the screening period have not returned to baseline or ≤ Grade 1 (NCI-CTCAE V5.0) (except for alopecia, or peripheral sensory neuropathy, which can be grade 2);
• 23) Patients with severe infections that are active or poorly controlled clinically. Patients with severe infections in the 4 weeks prior to initial dosing, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia;
• 24) Use of immunosuppressive drugs within 4 weeks prior to initial administration, excluding nasal, inhaled, or other routes of topical corticosteroids or physiological doses of systemic corticosteroids (i.e., no more than 10mg/ day of prednisone or equivalent doses of other corticosteroids); To allow temporary use of glucocorticoids for the treatment of breathing difficulties in diseases such as asthma and chronic obstructive pulmonary disease;
• 25) Patients who received live attenuated vaccine within 4 weeks prior to initial administration or who planned to receive live attenuated vaccine during the study period;
• 26) Patients who received major surgical treatment or significant traumatic injury 4 weeks prior to initial dosing
• 27) Patients who received traditional Chinese medicine with anti-tumor indications within 2 weeks prior to the first dose;
• 28) Patients with a history of gastrointestinal perforation or abscess within 6 months prior to enrollment;
• 29) Received treatment in other clinical trials within 4 weeks prior to initial dosing;
• 30) Patients whose urine routine indicated urinary protein ≥2+, or 24-hour urinary protein quantity >1.0g;
• 31) The presence of any active autoimmune disease or history of autoimmune disease (e.g., but not limited to: autoimmune hepatitis, interstitial pneumonia, enteritis, vasculitis, nephritis); Patients with asthma requiring medical intervention with bronchodilators were not included); However, the following patients were admitted: vitiligo, psoriasis, alopecia, well-controlled type I diabetes without systemic therapy, hypothyroidism with normal thyroid function treated by replacement therapy;
• 32) Other acute or chronic medical conditions, psychiatric disorders, or abnormalities in laboratory test values that may contribute to these results: increase the risk associated with study participation or study drug administration, or interfere with the interpretation of study results, and, in the investigator's judgment, classify patients as ineligible to participate in the study;
• 33) Other situations deemed unsuitable for inclusion by the researcher.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

The First Affiliated Hospital of Xiamen University

OTHER

Sponsor Role: lead

Responsible Party

Mingquan Cai

Director of medical oncology

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Mingquan Cai

Role: PRINCIPAL_INVESTIGATOR

The First Affiliated Hospital of Xiamen University

Xia Lv

Role: PRINCIPAL_INVESTIGATOR

Xiamen Humanity Hospital

Jun Qiu

Role: PRINCIPAL_INVESTIGATOR

Xiamen Humanity Hospital

Huita Wu

Role: PRINCIPAL_INVESTIGATOR

Zhongshan Hospital Affiliated to Xiamen University

Xiuping Zhang

Role: PRINCIPAL_INVESTIGATOR

Zhongshan Hospital (Xiamen), Fudan University

Xiaojian Yin

Role: PRINCIPAL_INVESTIGATOR

Xiamen Changgeng Hospital

Jinfeng Zhu

Role: PRINCIPAL_INVESTIGATOR

Quanzhou First Hospital

Wen Chen

Role: PRINCIPAL_INVESTIGATOR

The Second Affiliated Hospital of Fujian Medical University

Yijun Wang

Role: PRINCIPAL_INVESTIGATOR

Zhangzhou Hospital

Guoqin Qiu

Role: PRINCIPAL_INVESTIGATOR

The 73rd Army Hospital

Yongmei Liu

Role: PRINCIPAL_INVESTIGATOR

West China Xiamen Hospital of Sichuan University

Locations

The First Affiliated Hospital of Xiamen University

Fuzhou, Fujian, China

Site Status: RECRUITING

Countries

China

Central Contacts

Mingquan Cai

Role: CONTACT

mingquan035@163.com

13696908231

Facility Contacts

Mingquan Cai

Role: primary

mingquan035@163.com

13696908231

Other Identifiers

23-OBU-FJ-GC-II-013

Identifier Type: -

Identifier Source: org_study_id